Tag: acromegaly market analysis

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Growth In Market Value Is Anticipated For The Acromegaly Market Between 2026 And 2030?

The market for acromegaly treatments has seen rapid expansion in recent years. It is anticipated to increase from $2.56 billion in 2025 to $3.01 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 17.5%. Historically, this growth can be ascribed to the limited availability of acromegaly diagnostic tools, a rising prevalence of growth hormone disorders, an expanding hospital and specialty clinic infrastructure, the adoption of conventional treatment methods, and increasing awareness of rare endocrine disorders.

The acromegaly market is projected to experience substantial expansion over the upcoming years. It is anticipated to reach a valuation of $5.84 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 18.1%. This projected growth is driven by factors such as the advancement of sophisticated somatostatin analogues, an increase in parenteral treatment alternatives, the growing embrace of precision medicine strategies, the rise of homecare and outpatient treatment paradigms, and the incorporation of digital health and remote monitoring technologies. Key trends anticipated within this period encompass the increased uptake of growth hormone measurement and IGF-I testing, a surge in the utilization of somatostatin analogues and dopamine agonists, the broadening scope of minimally invasive surgery and radiation therapy, an intensifying emphasis on tailored treatment regimens for patients, and improved awareness and initiatives for early diagnosis.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12913&type=smp

What Influential Factors Are Boosting The Acromegaly Market Demand?

The rising occurrence of hormonal ailments, such as diabetes, is projected to stimulate expansion within the acromegaly market. Hormonal diseases, also termed endocrine disorders, represent health conditions that emerge from a malfunction in the endocrine system. Diabetes is recognized as one of the most widespread and significant hormonal diseases. Acromegaly and various other endocrine conditions can arise from the excessive production of certain hormones, including growth hormone or cortisol. Additionally, due to the influence of high levels of growth hormone on insulin synthesis, around 50% of individuals suffering from acromegaly may develop insulin resistance or type 2 diabetes mellitus. For instance, in March 2024, data from the Office for Health Improvement and Disparities, a UK-based government department, indicated that from March 2022 to March 2023, the percentage of people with type 1 diabetes who received all eight recommended care processes increased by 22%, while for type 2 diabetes, this percentage grew by 21%. During the same period, the percentage achieving target HbA1c levels climbed to 37.9%, representing the highest value ever reported by the National Diabetes Audit (NDA). Therefore, the increasing number of hormonal diseases is propelling the growth of the acromegaly market.

What Are The Major Segment Categories Within The Acromegaly Market?

The acromegaly market covered in this report is segmented –

1) By Type: Ectopic Acromegaly, Acromegaly Due To Growth Hormone

2) By Diagnosis: GH And IGF-I Measurement, Growth Hormone Suppression Test, Imaging, Other Diagnosis

3) By Route Of Administration: Oral, Parental, Other Routes Of Administration

4) By Treatment: Medication, Somatostatin analogues, Dopamine Agonists, Growth Hormone Antagonist, Surgery, Radiation, Other Treatments

5) By End Users: Hospitals, Specialty Clinics, Other End Users

Subsegments:

1) By Ectopic Acromegaly: Tumor-Induced Ectopic Acromegaly, Non-Tumor-Induced Ectopic Acromegaly

2) By Acromegaly Due To Growth Hormone: Primary Growth Hormone Excess, Secondary Growth Hormone Excess

What Trends Are Affecting The Growth Of The Acromegaly Market?

Companies operating within the acromegaly market are primarily focused on developing innovative products and solutions, such as generic lanreotide, to improve treatment options and patient outcomes. Generic lanreotide refers to an unbranded formulation of the medicine used for treating acromegaly and certain neuroendocrine tumors. It functions as a somatostatin analogue, effectively reducing growth hormone secretion and enhancing patient accessibility to effective treatment options. For example, in October 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company concentrating on generic drugs, launched the first and only generic version of Sandostatin LAR Depot in the United States. This injectable suspension, octreotide acetate, is indicated for addressing acromegaly and severe diarrhea associated with carcinoid syndrome. This launch significantly improves access to crucial therapy for patients requiring these treatments.

Who Are The Firms Contributing To The Acromegaly Market Ecosystem?

Major companies operating in the acromegaly market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH., Amgen Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Pharma S.A., Hikma Pharmaceuticals PLC, Lupin Ltd., Recordati S.p.A., Ionis Pharmaceuticals Inc., Amryt Pharma plc , Strongbridge Biopharma plc, Aquestive Therapeutics Inc., Peptron Inc., Crinetics Pharmaceuticals, Chiasma Inc.

Access The Complete Acromegaly Market Report:

https://www.thebusinessresearchcompany.com/report/acromegaly-global-market-report

Which Region Accounts For The Highest Share Of The Acromegaly Market?

North America was the largest region in the acromegaly market in 2025. The regions covered in the acromegaly market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Acromegaly Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=12913&type=smp

Browse Through More Reports Similar to the Global Acromegaly Market 2026, By The Business Research Company

Thrombophilia Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/thrombophilia-global-market-report

Hormone Therapy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report

Mastopexy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/mastopexy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Growth In Market Value Is Anticipated For The Acromegaly Market Between 2026 And 2030?

The market for acromegaly treatments has seen rapid expansion in recent years. It is anticipated to increase from $2.56 billion in 2025 to $3.01 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 17.5%. Historically, this growth can be ascribed to the limited availability of acromegaly diagnostic tools, a rising prevalence of growth hormone disorders, an expanding hospital and specialty clinic infrastructure, the adoption of conventional treatment methods, and increasing awareness of rare endocrine disorders.

The acromegaly market is projected to experience substantial expansion over the upcoming years. It is anticipated to reach a valuation of $5.84 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 18.1%. This projected growth is driven by factors such as the advancement of sophisticated somatostatin analogues, an increase in parenteral treatment alternatives, the growing embrace of precision medicine strategies, the rise of homecare and outpatient treatment paradigms, and the incorporation of digital health and remote monitoring technologies. Key trends anticipated within this period encompass the increased uptake of growth hormone measurement and IGF-I testing, a surge in the utilization of somatostatin analogues and dopamine agonists, the broadening scope of minimally invasive surgery and radiation therapy, an intensifying emphasis on tailored treatment regimens for patients, and improved awareness and initiatives for early diagnosis.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12913&type=smp

What Influential Factors Are Boosting The Acromegaly Market Demand?

The rising occurrence of hormonal ailments, such as diabetes, is projected to stimulate expansion within the acromegaly market. Hormonal diseases, also termed endocrine disorders, represent health conditions that emerge from a malfunction in the endocrine system. Diabetes is recognized as one of the most widespread and significant hormonal diseases. Acromegaly and various other endocrine conditions can arise from the excessive production of certain hormones, including growth hormone or cortisol. Additionally, due to the influence of high levels of growth hormone on insulin synthesis, around 50% of individuals suffering from acromegaly may develop insulin resistance or type 2 diabetes mellitus. For instance, in March 2024, data from the Office for Health Improvement and Disparities, a UK-based government department, indicated that from March 2022 to March 2023, the percentage of people with type 1 diabetes who received all eight recommended care processes increased by 22%, while for type 2 diabetes, this percentage grew by 21%. During the same period, the percentage achieving target HbA1c levels climbed to 37.9%, representing the highest value ever reported by the National Diabetes Audit (NDA). Therefore, the increasing number of hormonal diseases is propelling the growth of the acromegaly market.

What Are The Major Segment Categories Within The Acromegaly Market?

The acromegaly market covered in this report is segmented –

1) By Type: Ectopic Acromegaly, Acromegaly Due To Growth Hormone

2) By Diagnosis: GH And IGF-I Measurement, Growth Hormone Suppression Test, Imaging, Other Diagnosis

3) By Route Of Administration: Oral, Parental, Other Routes Of Administration

4) By Treatment: Medication, Somatostatin analogues, Dopamine Agonists, Growth Hormone Antagonist, Surgery, Radiation, Other Treatments

5) By End Users: Hospitals, Specialty Clinics, Other End Users

Subsegments:

1) By Ectopic Acromegaly: Tumor-Induced Ectopic Acromegaly, Non-Tumor-Induced Ectopic Acromegaly

2) By Acromegaly Due To Growth Hormone: Primary Growth Hormone Excess, Secondary Growth Hormone Excess

What Trends Are Affecting The Growth Of The Acromegaly Market?

Companies operating within the acromegaly market are primarily focused on developing innovative products and solutions, such as generic lanreotide, to improve treatment options and patient outcomes. Generic lanreotide refers to an unbranded formulation of the medicine used for treating acromegaly and certain neuroendocrine tumors. It functions as a somatostatin analogue, effectively reducing growth hormone secretion and enhancing patient accessibility to effective treatment options. For example, in October 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company concentrating on generic drugs, launched the first and only generic version of Sandostatin LAR Depot in the United States. This injectable suspension, octreotide acetate, is indicated for addressing acromegaly and severe diarrhea associated with carcinoid syndrome. This launch significantly improves access to crucial therapy for patients requiring these treatments.

Who Are The Firms Contributing To The Acromegaly Market Ecosystem?

Major companies operating in the acromegaly market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH., Amgen Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Pharma S.A., Hikma Pharmaceuticals PLC, Lupin Ltd., Recordati S.p.A., Ionis Pharmaceuticals Inc., Amryt Pharma plc , Strongbridge Biopharma plc, Aquestive Therapeutics Inc., Peptron Inc., Crinetics Pharmaceuticals, Chiasma Inc.

Access The Complete Acromegaly Market Report:

https://www.thebusinessresearchcompany.com/report/acromegaly-global-market-report

Which Region Accounts For The Highest Share Of The Acromegaly Market?

North America was the largest region in the acromegaly market in 2025. The regions covered in the acromegaly market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Acromegaly Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=12913&type=smp

Browse Through More Reports Similar to the Global Acromegaly Market 2026, By The Business Research Company

Thrombophilia Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/thrombophilia-global-market-report

Hormone Therapy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report

Mastopexy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/mastopexy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Acromegaly Market Between 2026 And 2030?

The acromegaly market size has seen a swift increase in recent years. The market is projected to expand from $2.56 billion in 2025 to $3.01 billion in 2026, driven by a compound annual growth rate (CAGR) of 17.5%. Historically, this expansion has been driven by the scarce availability of acromegaly diagnostic tools, a rising prevalence of growth hormone disorders, the expansion of hospital and specialty clinic infrastructure, the uptake of conventional treatment methods, and increasing awareness of rare endocrine disorders.

The acromegaly market is anticipated to experience substantial growth over the next few years. It is projected to expand to $5.84 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 18.1%. This projected growth can be attributed to several factors, including the advancement of somatostatin analogues, an increase in parenteral treatment options, the growing adoption of precision medicine, the rise of homecare and outpatient treatment models, and the integration of digital health and remote monitoring technologies. Key trends during this period are expected to include a greater emphasis on growth hormone measurement and IGF-I testing, increased application of somatostatin analogues and dopamine agonists, the expansion of minimally invasive surgical techniques and radiation therapy, an enhanced focus on tailored treatment plans for patients, and improvements in awareness and early diagnosis initiatives.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/acromegaly-global-market-report

Which Strong Drivers Are Impacting The Acromegaly Market Growth?

The rising incidence of hormonal conditions, such as diabetes, is projected to drive expansion in the acromegaly market. Hormonal diseases, also identified as endocrine disorders, are medical issues resulting from a malfunction within the endocrine system. Diabetes is recognized as one of the most widespread and significant hormonal ailments. Acromegaly, along with other endocrine illnesses, can arise from an excessive production of specific hormones, including growth hormone or cortisol. Moreover, given the influence of high growth hormone levels on insulin synthesis, approximately 50% of individuals with acromegaly are susceptible to developing insulin resistance or type 2 diabetes mellitus. For example, in March 2024, the Office for Health Improvement and Disparities, a UK-based government body, reported that between March 2022 and March 2023, the proportion of people with type 1 diabetes receiving all eight recommended care processes climbed by 22%, and for type 2 diabetes, it grew by 21%. During the same period, the percentage achieving target HbA1c levels reached 37.9%, marking the highest figure ever recorded by the National Diabetes Audit (NDA). Hence, the increasing prevalence of hormonal diseases is serving as a primary catalyst for the growth of the acromegaly market.

What Are The Key Segment Divisions In The Acromegaly Market Segment Structure?

The acromegaly market covered in this report is segmented –

1) By Type: Ectopic Acromegaly, Acromegaly Due To Growth Hormone

2) By Diagnosis: GH And IGF-I Measurement, Growth Hormone Suppression Test, Imaging, Other Diagnosis

3) By Route Of Administration: Oral, Parental, Other Routes Of Administration

4) By Treatment: Medication, Somatostatin analogues, Dopamine Agonists, Growth Hormone Antagonist, Surgery, Radiation, Other Treatments

5) By End Users: Hospitals, Specialty Clinics, Other End Users

Subsegments:

1) By Ectopic Acromegaly: Tumor-Induced Ectopic Acromegaly, Non-Tumor-Induced Ectopic Acromegaly

2) By Acromegaly Due To Growth Hormone: Primary Growth Hormone Excess, Secondary Growth Hormone Excess

Which Trends Are Contributing To Changes In The Acromegaly Market?

Leading companies in the acromegaly market are concentrating on creating innovative products and solutions, such as generic lanreotide, to enhance treatment possibilities and improve patient outcomes. Generic lanreotide is defined as an unbranded formulation of the medicine used for treating acromegaly and certain neuroendocrine tumors. It functions as a somatostatin analogue, which reduces growth hormone secretion and increases patient accessibility to effective treatment options. For example, in October 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company focused on generic drugs, introduced the first and only generic version of Sandostatin LAR Depot in the United States. The injectable suspension, octreotide acetate, is indicated for managing acromegaly and severe diarrhea associated with carcinoid syndrome. This introduction significantly improves access to crucial therapy for patients who require these treatments.

Which Organizations Are Engaged In The Acromegaly Market?

Major companies operating in the acromegaly market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH., Amgen Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Pharma S.A., Hikma Pharmaceuticals PLC, Lupin Ltd., Recordati S.p.A., Ionis Pharmaceuticals Inc., Amryt Pharma plc , Strongbridge Biopharma plc, Aquestive Therapeutics Inc., Peptron Inc., Crinetics Pharmaceuticals, Chiasma Inc.

Get The Full Acromegaly Market Report:

https://www.thebusinessresearchcompany.com/report/acromegaly-global-market-report

Which Region Represents The Largest Share Of The Acromegaly Market?

North America was the largest region in the acromegaly market in 2025. The regions covered in the acromegaly market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Acromegaly Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/acromegaly-global-market-report

Browse Through More Reports Similar to the Global Acromegaly Market 2026, By The Business Research Company

Mastopexy Market Report 2026

https://www.thebusinessresearchcompany.com/report/mastopexy-global-market-report

Thrombophilia Market Report 2026

https://www.thebusinessresearchcompany.com/report/thrombophilia-global-market-report

Hormone Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Acromegaly Market At The End Of The 2026–2030 Forecast Period?

The acromegaly market has experienced swift expansion in recent years. It is anticipated to increase from $2.56 billion in 2025 to $3.01 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 17.5%. The historical growth of this market can be linked to several factors, including the constrained availability of diagnostic tools for acromegaly, a rising occurrence of growth hormone disorders, the development of hospital and specialty clinic infrastructure, the adoption of conventional treatment methods, and an increasing understanding of rare endocrine disorders.

The acromegaly market is projected to experience substantial expansion in the coming years. It is forecast to reach $5.84 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 18.1%. This growth during the forecast period is primarily driven by the advancement of sophisticated somatostatin analogues, an increase in parenteral treatment availability, the growing embrace of precision medicine strategies, the proliferation of homecare and outpatient treatment models, and the incorporation of digital health and remote monitoring technologies. Key trends anticipated within this period involve the greater uptake of growth hormone measurement and IGF-I testing, an increasing application of somatostatin analogues and dopamine agonists, the broader implementation of minimally invasive surgery and radiation therapy, a heightened emphasis on individualized treatment strategies for patients, and improved awareness and early diagnostic initiatives.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12913&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Acromegaly Market?

The acromegaly market is anticipated to experience growth driven by the increasing incidence of hormonal diseases such as diabetes. Hormonal diseases, also recognized as endocrine disorders, are medical conditions that arise from a malfunction in the endocrine system. Diabetes represents one of the most prevalent and significant hormonal diseases. Acromegaly, alongside other endocrine diseases, can be caused by the excessive production of certain hormones, including growth hormone or cortisol. Furthermore, about 50% of individuals with acromegaly may develop insulin resistance or type 2 diabetes mellitus due to the effect of elevated growth hormone on insulin synthesis. For instance, according to the Office for Health Improvement and Disparities, a UK-based government department, in March 2024, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22% between March 2022 and March 2023, while for type 2 diabetes, it rose by 21%. During the same period, the percentage achieving target HbA1c levels ascended to 37.9%, which marked the highest value ever reported by the National Diabetes Audit (NDA). Consequently, the rising number of hormonal diseases is a key factor propelling the growth of the acromegaly market.

What Segment Types Make Up The Acromegaly Market?

The acromegaly market covered in this report is segmented –

1) By Type: Ectopic Acromegaly, Acromegaly Due To Growth Hormone

2) By Diagnosis: GH And IGF-I Measurement, Growth Hormone Suppression Test, Imaging, Other Diagnosis

3) By Route Of Administration: Oral, Parental, Other Routes Of Administration

4) By Treatment: Medication, Somatostatin analogues, Dopamine Agonists, Growth Hormone Antagonist, Surgery, Radiation, Other Treatments

5) By End Users: Hospitals, Specialty Clinics, Other End Users

Subsegments:

1) By Ectopic Acromegaly: Tumor-Induced Ectopic Acromegaly, Non-Tumor-Induced Ectopic Acromegaly

2) By Acromegaly Due To Growth Hormone: Primary Growth Hormone Excess, Secondary Growth Hormone Excess

Which Market Trends Are Creating New Opportunities In The Acromegaly Market?

Major companies operating in the acromegaly market are actively pursuing the development of innovative products and solutions, including generic lanreotide, to expand treatment possibilities and enhance patient outcomes. Generic lanreotide refers to an unbranded formulation of the drug used to manage acromegaly and specific neuroendocrine tumors, acting as a somatostatin analogue to reduce growth hormone secretion and improve patient accessibility to effective therapeutic options. For instance, in October 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company focused on generic drugs, launched the first and only generic version of Sandostatin LAR Depot in the United States. This injectable suspension, octreotide acetate, is indicated for the treatment of acromegaly and severe diarrhea associated with carcinoid syndrome, thereby improving access to crucial therapy for patients requiring these treatments.

Who Are The Key Players Driving Competition In The Acromegaly Market?

Major companies operating in the acromegaly market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH., Amgen Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Pharma S.A., Hikma Pharmaceuticals PLC, Lupin Ltd., Recordati S.p.A., Ionis Pharmaceuticals Inc., Amryt Pharma plc , Strongbridge Biopharma plc, Aquestive Therapeutics Inc., Peptron Inc., Crinetics Pharmaceuticals, Chiasma Inc.

Read the full acromegaly market report here:

https://www.thebusinessresearchcompany.com/report/acromegaly-global-market-report

Which Regions Are Projected To Dominate The Acromegaly Market In The Coming Years?

North America was the largest region in the acromegaly market in 2025. The regions covered in the acromegaly market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Acromegaly Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12913&type=smp

Browse Through More Reports Similar to the Global Acromegaly Market 2026, By The Business Research Company

thrombophilia global market report

https://www.thebusinessresearchcompany.com/report/thrombophilia-global-market-report

hormone therapy global market report

https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report

mastopexy global market report

https://www.thebusinessresearchcompany.com/report/mastopexy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Acromegaly Market At The End Of The 2026–2030 Forecast Period?

The acromegaly market has experienced swift expansion in recent years. It is anticipated to increase from $2.56 billion in 2025 to $3.01 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 17.5%. The historical growth of this market can be linked to several factors, including the constrained availability of diagnostic tools for acromegaly, a rising occurrence of growth hormone disorders, the development of hospital and specialty clinic infrastructure, the adoption of conventional treatment methods, and an increasing understanding of rare endocrine disorders.

The acromegaly market is projected to experience substantial expansion in the coming years. It is forecast to reach $5.84 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 18.1%. This growth during the forecast period is primarily driven by the advancement of sophisticated somatostatin analogues, an increase in parenteral treatment availability, the growing embrace of precision medicine strategies, the proliferation of homecare and outpatient treatment models, and the incorporation of digital health and remote monitoring technologies. Key trends anticipated within this period involve the greater uptake of growth hormone measurement and IGF-I testing, an increasing application of somatostatin analogues and dopamine agonists, the broader implementation of minimally invasive surgery and radiation therapy, a heightened emphasis on individualized treatment strategies for patients, and improved awareness and early diagnostic initiatives.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12913&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Acromegaly Market?

The acromegaly market is anticipated to experience growth driven by the increasing incidence of hormonal diseases such as diabetes. Hormonal diseases, also recognized as endocrine disorders, are medical conditions that arise from a malfunction in the endocrine system. Diabetes represents one of the most prevalent and significant hormonal diseases. Acromegaly, alongside other endocrine diseases, can be caused by the excessive production of certain hormones, including growth hormone or cortisol. Furthermore, about 50% of individuals with acromegaly may develop insulin resistance or type 2 diabetes mellitus due to the effect of elevated growth hormone on insulin synthesis. For instance, according to the Office for Health Improvement and Disparities, a UK-based government department, in March 2024, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22% between March 2022 and March 2023, while for type 2 diabetes, it rose by 21%. During the same period, the percentage achieving target HbA1c levels ascended to 37.9%, which marked the highest value ever reported by the National Diabetes Audit (NDA). Consequently, the rising number of hormonal diseases is a key factor propelling the growth of the acromegaly market.

What Segment Types Make Up The Acromegaly Market?

The acromegaly market covered in this report is segmented –

1) By Type: Ectopic Acromegaly, Acromegaly Due To Growth Hormone

2) By Diagnosis: GH And IGF-I Measurement, Growth Hormone Suppression Test, Imaging, Other Diagnosis

3) By Route Of Administration: Oral, Parental, Other Routes Of Administration

4) By Treatment: Medication, Somatostatin analogues, Dopamine Agonists, Growth Hormone Antagonist, Surgery, Radiation, Other Treatments

5) By End Users: Hospitals, Specialty Clinics, Other End Users

Subsegments:

1) By Ectopic Acromegaly: Tumor-Induced Ectopic Acromegaly, Non-Tumor-Induced Ectopic Acromegaly

2) By Acromegaly Due To Growth Hormone: Primary Growth Hormone Excess, Secondary Growth Hormone Excess

Which Market Trends Are Creating New Opportunities In The Acromegaly Market?

Major companies operating in the acromegaly market are actively pursuing the development of innovative products and solutions, including generic lanreotide, to expand treatment possibilities and enhance patient outcomes. Generic lanreotide refers to an unbranded formulation of the drug used to manage acromegaly and specific neuroendocrine tumors, acting as a somatostatin analogue to reduce growth hormone secretion and improve patient accessibility to effective therapeutic options. For instance, in October 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company focused on generic drugs, launched the first and only generic version of Sandostatin LAR Depot in the United States. This injectable suspension, octreotide acetate, is indicated for the treatment of acromegaly and severe diarrhea associated with carcinoid syndrome, thereby improving access to crucial therapy for patients requiring these treatments.

Who Are The Key Players Driving Competition In The Acromegaly Market?

Major companies operating in the acromegaly market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH., Amgen Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Pharma S.A., Hikma Pharmaceuticals PLC, Lupin Ltd., Recordati S.p.A., Ionis Pharmaceuticals Inc., Amryt Pharma plc , Strongbridge Biopharma plc, Aquestive Therapeutics Inc., Peptron Inc., Crinetics Pharmaceuticals, Chiasma Inc.

Read the full acromegaly market report here:

https://www.thebusinessresearchcompany.com/report/acromegaly-global-market-report

Which Regions Are Projected To Dominate The Acromegaly Market In The Coming Years?

North America was the largest region in the acromegaly market in 2025. The regions covered in the acromegaly market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Acromegaly Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12913&type=smp

Browse Through More Reports Similar to the Global Acromegaly Market 2026, By The Business Research Company

thrombophilia global market report

https://www.thebusinessresearchcompany.com/report/thrombophilia-global-market-report

hormone therapy global market report

https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report

mastopexy global market report

https://www.thebusinessresearchcompany.com/report/mastopexy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model